Equity OfferingApr 9, 2026, 06:21 AM
Forte Biosciences Announces Public Offering of 5.7 Million Shares at $26.27, Targeting $150 Million in Gross Proceeds
AI Summary
Forte Biosciences, Inc. has entered into an underwriting agreement with Guggenheim Securities, LLC for a public offering of 5,709,936 shares of its common stock at a price of $26.27 per share. This offering is expected to generate approximately $150 million in gross proceeds for the company, before deducting underwriting discounts and other expenses. The company anticipates net proceeds of about $141 million, which could increase to approximately $162 million if the underwriters fully exercise their option to purchase additional shares. This capital raise will bolster the company's financial position, providing funds for general corporate purposes, though it will result in dilution for existing shareholders.
Key Highlights
- Forte Biosciences is offering 5,709,936 shares of common stock in a public offering.
- The shares are priced at $26.27 per share.
- The offering is expected to generate approximately $150 million in gross proceeds.
- The company anticipates net proceeds of approximately $141 million, or $162 million if the underwriters' option is fully exercised.
- Underwriters have a 30-day option to purchase up to an additional 856,490 shares.
- Guggenheim Securities, LLC is acting as the representative for the underwriters.
- The offering is expected to close on or about April 10, 2026.